Mankind Pharma Ltd is trading at ₹2,511.4, gaining 2% during the current session as of 12:49 IST on the NSE, according to reports from Business Standard. The stock has demonstrated strong momentum, rising for the fifth consecutive session and gaining approximately 19.34% over the past month. This performance contrasts with the broader market, where the benchmark NIFTY is down around 0.4% at 23,783.6 and the Sensex stands at 75,701.49, also down 0.4%.
The Nifty Pharma index, of which Mankind Pharma is a constituent, has gained approximately 9.71% in the last month and is currently quoted at 24,551.05, up 0.39% on the day, as reported by Business Standard. This sector performance shows resilience compared to the broader market decline, with the Nifty Pharma index down 13.93% over the past year, while Mankind Pharma has declined 2.38% year-on-year. The stock's trading volume today stood at 7.22 lakh shares, compared to the daily average of 5.15 lakh shares over the last month.
The benchmark May futures contract for Mankind Pharma is trading at ₹2,486.3, gaining 1.66% on the day, according to Business Standard reports. The futures price represents a premium to the current spot price, indicating positive sentiment in the derivatives market for the pharmaceutical stock.
The stock's Price-to-Earnings ratio stands at 57.52 based on trailing twelve months earnings ending December 25, as reported by Business Standard. This valuation metric reflects the premium pricing of the pharmaceutical stock in the current market environment.
